A 2026 single-cell and spatial-transcriptomics study of 21,156 brain immune cells found that late amyloid disease shifted interferon-driven neuroinflammation from microglia toward plaque-associated CD8 T cells, with T-cell frequency strongly tracking total amyloid deposits (Spearman rho = 0.844, p < 0.0001).1 The result does not turn Alzheimer’s disease into an autoimmune disease, but it makes …
A 2026 pilot randomized trial in 16 frail adults with multiple sclerosis found that 6 weeks of supervised multimodal exercise was feasible: retention was 87.5%, adherence was 97.2%, no adverse events were recorded, and fatigue and quality-of-life scores moved more than they did with waitlist control.1 Research Highlights Feasibility cleared the prespecified bar: 14 of …
A 2026 medRxiv preprint found that a training-free speech biomarker tracked dysarthria severity across 890 speakers, 10 corpora, and 5 full-pipeline languages, with all 5 consonant d-prime features showing random-effects correlations with clinical severity (rho = −0.50 to −0.56; all p < 2e−4). Research Highlights Speech-severity signal was broad: Muller et al. evaluated 890 speakers …
A 2026 medRxiv case-control study found that serum myelin oligodendrocyte glycoprotein was 20.5 pg/ml higher in multiple sclerosis than in healthy donors and 15.3 pg/ml higher during relapse than remission, making it a plausible blood marker of demyelination rather than a replacement for neurofilament light chain. Research Highlights MOG was higher in MS: serum myelin …
A 2026 cerebrospinal-fluid proteomics preprint involving 87 amyotrophic lateral sclerosis (ALS) patients, 89 healthy controls, and 61 neurological controls reported 399 ALS candidate proteins, complement markers that tracked disease stage, and a 5-protein panel that classified ALS vs. healthy controls with ROC AUC 0.95 after the best-known neurodegeneration markers were removed.1 Research Highlights CSF proteomics …
A 2026 PRO-ACT analysis of amyotrophic lateral sclerosis (ALS) trial data found a signal that ordinary ALSFRS total-score slopes cannot even express: Shannon entropy trajectories diverged between pooled active and placebo arms, including a 5-month delay in peak Fine Motor distributional spread for active-arm patients.1 Research Highlights Entropy found an endpoint-level signal: Rodriguez analyzed 7,512 …
A 2026 individual participant data meta-analysis of 1,721 dementia trial participants linked risperidone to cerebrovascular adverse events, HR 4.11 (95% CI 1.77 to 9.51), and major cardiovascular adverse events, HR 2.00 (95% CI 1.23 to 3.26).1 The timing signal is the practical warning: median first cerebrovascular event appeared at 4.3 weeks, and median first major …